NASDAQ NMS - GLOBAL MARKET · TNXP
-1.29% · -$0.1400 · Vol 525.0K
Market closed · last close 4:00 PM ET · price as of 19:41:29 ET
Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp

Biotechnology
$10.73
Card
Relationship Map

Follow $TNXP

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $TNXP by email

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology
Analyst data unavailable at compute time · Sentiment absence reason unknown
TNXP
Tonix Pharmaceuticals Holding Corp
Mon Sep 21 · market closed · Markets closed · resumes Tue 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

49/ 100
Veridion Score
Middle range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: LOW · 4 of 6 factors measured · Mon Sep 21 · market closed · Markets closed · resumes Tue 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is TNXP moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading TNXP catalysts
About Tonix Pharmaceuticals Holding Corp
PHARMACEUTICAL PREPARATIONS
Listed since
2009
Employees
142
Country
US

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$10.97
Day high
$11.08
Day low
$10.52
Previous close
$10.87
52W high
$26.78
-59.93% from high
52W low
$9.51
7% of range
Market cap
$186.4M
EPS
$-12.8200
Beta
0.93
Shares out
17.2M
Volume
525K
1.10× rel vol
Avg volume
476.5K
VWAP
$10.71
Price history computed in-house
1W
-7.66%
1M
-14.50%
3M
-11.32%
1Y
-59.93%
YTD
-31.31%
SMA 50 $11.95 · below
SMA 200 $13.93 · below
52W position 7%

TNXP overview

Loading financial statements
Loading TNXP Form 4 filings
Public disclosures

Congress activity in TNXP

No receipt-qualified Congressional disclosure is present for TNXP in the cached public ledger.

Federal contracts

TNXP contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for TNXP in this window.
Lobbying spend

TNXP lobbying filings, year to date.

Registered lobbying filings matched to Tonix Pharmaceuticals Holding Corp.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for TNXP in this window.
Loading news for TNXP
Analyst ratings
Sovereign unlock shows live analyst consensus for TNXP.
Options
Sovereign unlock shows live options positioning for TNXP.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.